Past, present, and future directions for defining optimal treatment outcome in depression - Remission and beyond

被引:296
作者
Keller, MB [1 ]
机构
[1] Brown Univ, Sch Med, Dept Psychiat & Human Behav, Providence, RI 02906 USA
来源
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION | 2003年 / 289卷 / 23期
关键词
D O I
10.1001/jama.289.23.3152
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
During the past decade, evidence from research on mood disorders has demonstrated that remission is the optimal outcome of treatment. However, there continues to be considerable variability in the specific characteristics that are accepted as indicators of remission. Increasing knowledge of mood disorders and their underlying mechanisms may allow for the development of a new diagnostic and assessment system that no longer is based solely on symptoms and other descriptive phenomena. Continued advances in neuroscience may allow for more knowledge of the underlying neurobiological status and more accurate assessments of the underlying disease state and response to treatment, thus enabling physicians to use treatments that will most effectively bring patients back to euthymia and a truly disease-free healthy state. Until then, remission should continue to be based on the descriptive and experiential phenomena of symptoms and psychosocial functioning.
引用
收藏
页码:3152 / 3160
页数:9
相关论文
共 128 条
[1]   Predictors of persistent social impairment among recovered depressed outpatients [J].
Agosti, V .
JOURNAL OF AFFECTIVE DISORDERS, 1999, 55 (2-3) :215-219
[2]   Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 1993 British Association for Psychopharmacology guidelines [J].
Anderson, IM ;
Nutt, DJ ;
Deakin, JFW .
JOURNAL OF PSYCHOPHARMACOLOGY, 2000, 14 (01) :3-20
[3]   Reboxetine, a new noradrenaline selective antidepressant, is at least as effective as fluoxetine in the treatment of depression [J].
Andreoli, V ;
Caillard, V ;
Deo, RS ;
Rybakowski, JK ;
Versiani, M .
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2002, 22 (04) :393-399
[4]  
[Anonymous], 1977, Research Diagnostic Criteria (RDC) for a Selected Group of Functional Disorders
[5]  
[Anonymous], 1997, ARCH INTERN MED, V157, P2413, DOI [10.1001/archinte.1997.00440420033005, DOI 10.1001/ARCHINTE.1997.00440420033005]
[6]  
BALDESSARINI RJ, 1999, JAMA-J AM MED ASSOC, V281, P323
[7]   The efficacy and tolerability of venlafaxine and paroxetine in outpatients with depressive disorder or dysthymia [J].
Ballús, C ;
Quiros, G ;
de Flores, T ;
de la Torre, J ;
Palao, D ;
Rojo, L ;
Gutiérrez, M ;
Casais, L ;
Riesgo, Y .
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2000, 15 (01) :43-48
[8]  
Beasley C M Jr, 1993, Ann Clin Psychiatry, V5, P199, DOI 10.3109/10401239309148983
[9]   FLUOXETINE VERSUS AMITRIPTYLINE IN THE TREATMENT OF MAJOR DEPRESSION - A MULTICENTER TRIAL [J].
BEASLEY, CM ;
SAYLER, ME ;
POTVIN, JH .
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 1993, 8 (03) :143-149
[10]   An open-label study of duloxetine hydrochloride, a mixed serotonin and noradrenaline reuptake inhibitor, in patients with DSM-III-R major depressive disorder [J].
Berk, M ;
duPlessis, AD ;
Birkett, M ;
Richardt, D .
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 1997, 12 (03) :137-140